DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Moleculin Biotech (MBRX) Deep Dive Analysis 2026
Executive Summary
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company dedicated to developing innovative therapies for hard-to-treat tumors and viruses. The company’s lead candidate, Annamycin, is advancing in the pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML), with the first unblinding of data anticipated in Q1 2026. This trial has expanded globally to nine countries, enhancing recruitment and diversity. Annamycin has demonstrated no evidence of cardiotoxicity across five clinical trials involving over 90 subjects, positioning it as a potential game-changer in anthracycline therapy. Additionally, investigator-initiated trials (IITs) are funded for pancreatic and brain cancers, broadening the pipeline. Financially, MBRX maintains a market capitalization of approximately $9.35 million, with recent capital raises supporting operations into Q1 2026. Key catalysts include interim data readouts and potential NDA filings, while risks encompass dilution from ongoing financing and binary trial outcomes. The company’s focus on next-generation anthracyclines and STAT3 inhibitors underscores its commitment to addressing unmet needs in oncology and virology.
Quick Data / Snapshot
| Ticker | MBRX |
|---|---|
| Market Cap | $9.35M |
| Current Stock Price | $4.59 (as of January 28, 2026 closing) |
| Cash | Approximately $6.7M (as of Q3 2025, with additional warrant exercises potentially extending runway) |
| Debt | Minimal, primarily operational with no significant long-term debt reported |
| Runway | Estimated into Q1 2026 based on current burn rate, with potential need for additional $7M funding |
| Shares Outstanding | 2,036,419 (post 1:25 reverse split in December 2025) |
| 52-Week High/Low | $91.25 / $3.13 |
| Average Daily Volume | ~148,821 shares |
| Next Earnings Report | Expected March 20, 2026 (Q4 2025) |
Source: Yahoo Finance, Latest 10-Q.
Company Overview
Moleculin Biotech, Inc., founded in 2015, is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in the development of novel therapies for cancers and viruses. The company originated from research at the M.D. Anderson Cancer Center, focusing on next-generation anthracyclines that overcome limitations of traditional chemotherapies, such as cardiotoxicity and multidrug resistance. Moleculin’s core technologies include Annamycin, a liposomal anthracycline designed for targeted delivery to tumors while sparing healthy tissues; the WP1066 Portfolio, which comprises STAT3 inhibitors aimed at modulating immune responses and tumor growth; and the WP1122 Portfolio, metabolism/glycolysis inhibitors with potential applications in oncology and antiviral treatments. As of January 2026, Moleculin has expanded its global footprint, with the MIRACLE trial operating across nine countries and over 46 sites. The company’s mission is to advance therapies for hard-to-treat indications, leveraging partnerships and investigator-initiated trials to accelerate development. With a lean operational structure, Moleculin emphasizes efficient capital use to reach key milestones. Source: Company Website, Latest 10-Q, Press Releases.
Pipeline / Main Products / Services
Moleculin’s pipeline is centered on three core platforms, each addressing significant unmet medical needs in oncology and virology.
Annamycin
Annamycin, Moleculin’s flagship candidate, is a next-generation anthracycline engineered to avoid cardiotoxicity—a major limitation of existing anthracyclines like doxorubicin—and bypass multidrug resistance mechanisms. It is currently in the pivotal Phase 3 MIRACLE trial (NCT06788756) for second-line relapsed/refractory AML, with treatment completion for the first 45 patients expected in Q1 2026 and initial unblinded data shortly thereafter. Blinded response activity is tracking within expected ranges, and the trial has expanded to nine countries for broader enrollment. Annamycin has shown promising early activity in multiple indications, including soft tissue sarcoma (STS) lung metastases, where it is also being evaluated. To date, no cardiotoxicity has been observed in over 90 subjects across five clinical trials. Additionally, Annamycin is set to enter its first clinical trial for pancreatic cancer in 2026. Source: ClinicalTrials.gov, Company PR.
WP1066 Portfolio
The WP1066 Portfolio consists of STAT3 inhibitors that target immune modulation and tumor suppression. WP1066 is in Phase 1/2 trials for brain tumors (e.g., glioblastoma) and pancreatic cancer, with IIT-funded studies underway. Recent data from pediatric brain tumor trials have shown immune response activation and potential efficacy, with further updates expected in 2026. Source: Company PR.
WP1122 Portfolio
WP1122 targets metabolism and glycolysis inhibition, with applications in antiviral therapies and oncology. It is in preclinical/early clinical stages, with potential expansion into viral indications like COVID-19 or other emerging viruses. Source: Company Website.
Financial Situation
As of the latest updates in early 2026, Moleculin has no revenue from product sales, relying on capital raises to fund operations. In Q3 2025, the company reported cash of $6.7M, with subsequent warrant exercises potentially adding to this. The annual burn rate is estimated at $20-25 million, primarily driven by R&D expenses for the MIRACLE trial and other programs. Debt remains minimal, with no significant long-term obligations. Recent dilution has occurred through offerings and warrants, including a 1:25 reverse split in December 2025 to maintain NASDAQ compliance. The runway is projected into Q1 2026, with a potential need for additional $7M in funding, assuming no major delays. Upcoming earnings for Q4 2025 are expected on March 20, 2026, with analysts forecasting an EPS of -$6.77. The company continues to explore non-dilutive funding via partnerships and grants for IITs. Source: SEC 10-Q, Yahoo Finance, Company PR.
Recent Timeline (Last 12 Months)
Below is a chronological timeline of key events for MBRX from February 2025 to January 2026, based on verified sources such as press releases, SEC filings, and earnings reports.
- February 2025: Issuance of warrants for potential raises. Part of an agreement to fund operations, with subsequent exercises generating funds throughout the year. Source: GlobeNewswire.
- May 2025: Release of Q1 2025 financial results (May 14). EPS reported at -$17.25, with focus on MIRACLE trial advancement and declining cash position. Beginning of EU trial site expansion. Source: Yahoo Finance Earnings.
- August 2025: Release of Q2 2025 financial results (August 13). EPS at -$12.25, with update on MIRACLE trial recruitment (Phase 2B/3 for AML), US/EU site openings, and anticipated data readout by end of 2025 (later revised to Q1 2026). Positive FDA feedback on pediatric plan for Annamycin in AML. Source: Moleculin PR.
- August 2025: Further issuance of warrants as part of financing, linked to subsequent exercises for ~$7.1M in Q3. Source: SEC Filings.
- November 2025: Release of Q3 2025 financial results (November 13). EPS at -$17, with cash at $6.7M and annual burn rate ~$20-25M. Update on MIRACLE: 60% of first 45 patients consented. Source: Yahoo Finance Earnings.
- November 2025: 1-for-25 reverse split (November 26). Approved to maintain NASDAQ compliance, reducing shares outstanding to ~2.04M. Stock price adjusted post-split. Source: Moleculin PR.
- December 2025: New collaboration for Annamycin in brain tumors (December 8). Agreement with CIC biomaGUNE for preclinical research on intra-arterial delivery for GBM (glioblastoma). Source: Moleculin PR.
- December 2025: Completion of treatment for first 45 patients in MIRACLE Phase 3 trial (December 10). On pace for unblinding in Q1 2026. Source: Moleculin PR.
- December 2025: Immediate exercise of warrants for ~$6.5M gross proceeds (December 10). Agreements with holders for exercises, with issuance of new warrants subject to shareholder approval. Closing on December 11, funds for working capital. Source: GlobeNewswire via Quiver.
- December 2025: Positive results from Phase 1 trial of WP1066 for recurrent pediatric brain tumors (December 17). Data show immune activation and potential efficacy. Source: Yahoo Finance News.
- December 2025: Filing for sale of 2.61M shares (December 23). Part of shelf registration for potential future raises. Source: Intellectia AI.
- December 2025: Confirmation of first MIRACLE unblinding in Q1 2026 (December 22). Update on global trial expansion (9 countries). Source: Investing.com.
- January 2026: Accelerated 2026 outlook (January 12). First MIRACLE unblinding in Q1, global expansion, funded IIT programs for pancreatic and brain cancer. Source: Moleculin PR.
- January 2026: Confirmation of no cardiotoxicity for Annamycin in 90 subjects (January 13). Independent assessment across 5 trials. Source: Moleculin PR.
Catalysts
– Q1 2026: First unblinding of MIRACLE Phase 3 trial data (45 patients), with potential for accelerated NDA if positive.
– H1 2026: Full Part A readout (75-90 patients) and initiation of pancreatic cancer trial.
– Throughout 2026: Updates from IITs in pancreatic and brain cancers, potential partnerships.
– H2 2026: Possible second unblinding and regulatory filings if data supports. Source:
Company PR,
ClinicalTrials.gov.
Management Analysis
The management team at Moleculin Biotech brings extensive experience in biotech startups, clinical development, and commercialization.
Walter V. Klemp – Founder, President, CEO, and Chairman
Co-founder with over 10 years at Moleculin, Klemp has a proven track record in building biotech companies. He served as CEO and Executive Chairman of Soliton, Inc., which he co-founded, took public on NASDAQ in 2018, and sold to AbbVie in 2020. Previously, he was President and CEO of Zeno Corporation (2004-2011), developing dermatology devices and drugs through FDA approval. From 1987-2000, he founded and led Drypers Corporation to the INC 500 list. His expertise in capital raises and clinical advancement is critical for Moleculin’s Phase 3 progress.
Michael D. Cannon – Director
With over 40 years in pharmaceuticals, Cannon was Chief Science Officer and EVP at SICOR, Inc. (1997-2004), acquired by Teva, focusing on generics and biopharmaceuticals. He oversaw international partnerships and facility licensures. He has served on multiple boards, including Athenex, Inc., and advises on healthcare investments.
Elizabeth Cermak – Director
A healthcare executive with 35+ years, Cermak was Chief Commercial Officer at POZEN and held senior roles at Johnson & Johnson, managing $750M portfolios. She serves on boards like Que Oncology and Clarus Therapeutics, bringing commercialization expertise.
John Climaco – Director
CEO of CNS Pharmaceuticals since 2017, Climaco has led healthcare firms like Perma-Fix Medical and Axial Biotech. He serves on boards including Digirad, Inc., with a Juris Doctorate from UC Hastings.
Robert E. George – Director
Former PwC partner with healthcare focus, George chairs the Audit Committee at UT Health Science Center and teaches at UT Austin.
Joy Yan, MD, PhD – Director
Oncology expert with experience at Ambrx, Bristol Myers Squibb, Janssen, and Bayer. Led approvals for nivolumab and ipilimumab. Holds MD from China Medical University and PhD from Johns Hopkins. Source: Company Board.
Analysts and Recent Target Prices
Consensus rating: Strong Buy from 3-4 analysts. Average target price: $24.33 (range $20-31), implying ~430% upside from $4.59. Some sources indicate higher averages, such as $61 from MarketBeat (range up to $100) or $52 from Fintel, but conservative estimates are used here based on consistent reports. Analysts highlight Annamycin’s safety profile and MIRACLE trial potential. Source: MarketBeat, Benzinga.
Sentiment
Sentiment on MBRX is mixed but leaning bullish among retail investors focused on catalysts. On Reddit, discussions highlight the stock’s potential for a run into 2026 data readouts, with some viewing it as undervalued at $50M market cap pre-catalysts. Bearish views cite dilution and post-split price struggles. On X (formerly Twitter), mentions are sparse and often promotional, with one user noting potential fractal patterns for recovery from $3 lows. Stocktwits sentiment is bearish overall, with themes around low volume and waiting for trial data. Note: These are opinions from non-professional traders and should not be relied upon for decisions.
Risks and Red Flags
– High dilution risk from warrants/offerings.
– Recent 1:25 reverse split (Dec 2025) signals price struggles.
– Binary trial outcomes; failure could tank stock.
– Low cash; potential further raises.
– Competition in AML space. Source:
PR, SEC filings.
Possible Scenarios
– Positive MIRACLE data: Stock surge, partnerships.
– Negative data: Further declines, delisting risk.
– Steady progress: Gradual recovery to analyst targets.
Final Synthesis / Bottom Line
MBRX offers high-risk/high-reward exposure to AML therapies with near-term catalysts. Monitor trial progress closely.
This content is for educational/informational purposes only and is not financial advice or an investment recommendation. Readers should conduct their own research and consult a licensed advisor. Compliant with CONSOB (Italy) and SEC (USA) guidelines. For legal details, see Merlintrader Legal.
Analisi Approfondita su Moleculin Biotech (MBRX) 2026
Riassunto Esecutivo
Moleculin Biotech, Inc. (NASDAQ: MBRX) è una società farmaceutica in fase 3 clinica dedicata allo sviluppo di terapie innovative per tumori e virus difficili da trattare. Il candidato principale, Annamycin, sta avanzando nel trial pivotale di fase 3 MIRACLE per la leucemia mieloide acuta recidivante/refrattaria (AML), con la prima sblocco dei dati previsto nel Q1 2026. Questo trial si è espanso globalmente in nove paesi, migliorando il reclutamento e la diversità. Annamycin ha dimostrato assenza di cardiotossicità in cinque trial clinici su oltre 90 soggetti, posizionandolo come potenziale game-changer nella terapia antraciclinica. Inoltre, trial investigator-initiated (IIT) sono finanziati per cancro pancreatico e cerebrale, ampliando la pipeline. Finanziariamente, MBRX ha una capitalizzazione di mercato di circa $9.35 milioni, con recenti aumenti di capitale che supportano le operazioni in Q1 2026. Catalyst chiave includono letture dati interim e potenziali filing NDA, mentre i rischi comprendono diluizione da finanziamenti in corso e outcomes binari dei trial. Il focus dell’azienda su antracicline di nuova generazione e inibitori STAT3 sottolinea il suo impegno a affrontare bisogni non soddisfatti in oncologia e virologia.
Dati Rapidi / Snapshot
| Ticker | MBRX |
|---|---|
| Capitalizzazione di Mercato | $9.35M |
| Prezzo Azionario Corrente | $4.59 (chiusura del 28 gennaio 2026) |
| Cassa | Circa $6.7M (al Q3 2025, con esercizi warrant aggiuntivi che potenzialmente estendono runway) |
| Debito | Minimo, principalmente operativo senza debiti a lungo termine significativi |
| Runway | Stimata in Q1 2026 basato su burn rate attuale, con potenziale bisogno di ulteriori $7M funding |
| Azioni in Circolazione | 2,036,419 (post reverse split 1:25 dicembre 2025) |
| Alto/Basso 52 Settimane | $91.25 / $3.13 |
| Volume Medio Giornaliero | ~148,821 azioni |
| Prossimo Report Earnings | Previsto 20 marzo 2026 (Q4 2025) |
Fonte: Yahoo Finance, Ultimo 10-Q.
Panoramica dell’Azienda
Moleculin Biotech, Inc., fondata nel 2015, è una società farmaceutica in fase clinica con sede a Houston, Texas, specializzata nello sviluppo di terapie innovative per cancri e virus. L’azienda origina da ricerche del M.D. Anderson Cancer Center, focalizzandosi su antracicline di nuova generazione che superano i limiti delle chemioterapie tradizionali, come cardiotossicità e resistenza multidroga. Le tecnologie core di Moleculin includono Annamycin, un’antraciclina liposomiale progettata per consegna mirata ai tumori risparmiando tessuti sani; il Portfolio WP1066, che comprende inibitori STAT3 mirati a modulare risposte immunitarie e crescita tumorale; e il Portfolio WP1122, inibitori del metabolismo/glicolisi con applicazioni in oncologia e trattamenti antivirali. Al gennaio 2026, Moleculin ha espanso la sua impronta globale, con il trial MIRACLE operativo in nove paesi e oltre 46 siti. La missione dell’azienda è avanzare terapie per indicazioni difficili da trattare, sfruttando partnership e trial investigator-initiated per accelerare lo sviluppo. Con una struttura operativa snella, Moleculin enfatizza l’uso efficiente del capitale per raggiungere milestone chiave. Fonte: Sito Aziendale, Ultimo 10-Q, Press Release.
Pipeline / Prodotti Principali / Servizi
La pipeline di Moleculin è centrata su tre piattaforme core, ciascuna affrontando bisogni medici non soddisfatti significativi in oncologia e virologia.
Annamycin
Annamycin, il candidato flagship di Moleculin, è un’antraciclina di nuova generazione ingegnerizzata per evitare cardiotossicità—un limite maggiore delle antracicline esistenti come doxorubicina—e bypassare meccanismi di resistenza multidroga. È attualmente nel trial pivotale di fase 3 MIRACLE (NCT06788756) per AML second-line recidivante/refrattaria, con completamento trattamento per i primi 45 pazienti previsto nel Q1 2026 e dati iniziali sbloccati poco dopo. L’attività di risposta cieca sta tracciando entro range attesi, e il trial si è espanso in nove paesi per reclutamento più ampio. Annamycin ha mostrato attività precoce promettente in multiple indicazioni, inclusi metastasi polmonari sarcoma dei tessuti molli (STS), dove è anche valutato. Ad oggi, nessuna cardiotossicità osservata in oltre 90 soggetti su cinque trial clinici. Inoltre, Annamycin è pronto a entrare nel suo primo trial clinico per cancro pancreatico nel 2026. Fonte: ClinicalTrials.gov, PR Aziendali.
Portfolio WP1066
Il Portfolio WP1066 consiste in inibitori STAT3 che mirano a modulazione immunitaria e soppressione tumorale. WP1066 è in trial fase 1/2 per tumori cerebrali (es. glioblastoma) e cancro pancreatico, con studi IIT finanziati in corso. Dati recenti da trial tumori cerebrali pediatrici hanno mostrato attivazione risposta immunitaria e potenziale efficacia, con ulteriori update attesi nel 2026. Fonte: PR Aziendali.
Portfolio WP1122
WP1122 mira a inibizione metabolismo e glicolisi, con applicazioni in terapie antivirali e oncologia. È in fasi precliniche/cliniche precoci, con potenziale espansione in indicazioni virali come COVID-19 o altri virus emergenti. Fonte: Sito Aziendale.
Situazione Finanziaria
Al gennaio 2026, Moleculin non ha revenue da vendite prodotti, affidandosi a aumenti capitale per finanziare operazioni. Nel Q3 2025, l’azienda ha riportato cassa di $6.7M, con esercizi warrant successivi che potenzialmente aggiungono a questo. Il burn rate annuo è stimato a $20-25 milioni, principalmente guidato da spese R&D per trial MIRACLE e altri programmi. Debito resta minimo, senza obblighi a lungo termine significativi. Diluizione recente tramite offerte e warrant, inclusa reverse split 1:25 dicembre 2025 per compliance NASDAQ. Runway proiettata in Q1 2026, con potenziale bisogno di ulteriori $7M in funding, assumendo no ritardi maggiori. Prossimi earnings Q4 2025 attesi 20 marzo 2026, con analisti che prevedono EPS di -$6.77. L’azienda continua a esplorare funding non-dilutivo via partnership e grant per IIT. Fonte: SEC 10-Q, Yahoo Finance, PR Aziendali.
Timeline Recente (Ultimi 12 Mesi)
Di seguito una timeline cronologica degli eventi chiave per MBRX da febbraio 2025 a gennaio 2026, basata su fonti verificate come press release, filing SEC e report earnings.
- Febbraio 2025: Emissione di warrant per potenziali raises. Parte di un accordo per finanziare operazioni, con esercizi successivi che hanno generato fondi nel corso dell’anno. Fonte: GlobeNewswire.
- Maggio 2025: Rilascio risultati finanziari Q1 2025 (14 maggio). EPS reported a -$17.25, con focus su avanzamento trial MIRACLE e cash position in calo. Inizio espansione siti trial in EU. Fonte: Yahoo Finance Earnings.
- Agosto 2025: Rilascio risultati finanziari Q2 2025 (13 agosto). EPS a -$12.25, con aggiornamento su reclutamento MIRACLE trial (fase 2B/3 per AML), apertura siti US/EU e anticipato data readout entro fine 2025 (poi rivisto a Q1 2026). Positiva FDA feedback su piano pediatrico per Annamycin in AML. Fonte: Moleculin PR.
- Agosto 2025: Ulteriore emissione di warrant come parte di financing, collegati a esercizi successivi per ~$7.1M in Q3. Fonte: SEC Filings.
- Novembre 2025: Rilascio risultati finanziari Q3 2025 (13 novembre). EPS a -$17, con cash a $6.7M e burn rate annuo ~$20-25M. Aggiornamento su MIRACLE: 60% dei primi 45 pazienti consenzienti. Fonte: Yahoo Finance Earnings.
- Novembre 2025: Reverse split 1-for-25 (26 novembre). Approvato per mantenere compliance NASDAQ, riducendo shares outstanding a ~2.04M. Stock price adjusted post-split. Fonte: Moleculin PR.
- Dicembre 2025: Nuova collaborazione per Annamycin in tumori cerebrali (8 dicembre). Accordo con CIC biomaGUNE per ricerca preclinica su delivery intra-arteriosa per GBM (glioblastoma). Fonte: Moleculin PR.
- Dicembre 2025: Completamento trattamento per i primi 45 pazienti in MIRACLE Phase 3 trial (10 dicembre). On pace per unblinding Q1 2026. Fonte: Moleculin PR.
- Dicembre 2025: Esercizio immediato di warrant per ~$6.5M gross proceeds (10 dicembre). Accordi con holder per esercizi, con emissione nuovi warrant soggetti ad approval azionisti. Chiusura 11 dicembre, fondi per working capital. Fonte: GlobeNewswire via Quiver.
- Dicembre 2025: Risultati positivi da Phase 1 trial WP1066 per tumori cerebrali pediatrici ricorrenti (17 dicembre). Dati mostrano attivazione risposta immunitaria e potenziale efficacia. Fonte: Yahoo Finance News.
- Dicembre 2025: Filing per vendita di 2.61M shares (23 dicembre). Parte di shelf registration per potenziali raises futuri. Fonte: Intellectia AI.
- Dicembre 2025: Conferma primo unblinding MIRACLE in Q1 2026 (22 dicembre). Aggiornamento su espansione globale trial (9 paesi). Fonte: Investing.com.
- Gennaio 2026: Accelerazione outlook 2026 (12 gennaio). Primo unblinding MIRACLE Q1, espansione globale, programmi IIT funded per pancreatico e brain cancer. Fonte: Moleculin PR.
- Gennaio 2026: Conferma assenza cardiotossicità Annamycin in 90 soggetti (13 gennaio). Valutazione indipendente su 5 trial. Fonte: Moleculin PR.
Catalyst
– Q1 2026: Prima sblocco dati trial MIRACLE fase 3 (45 pazienti), con potenziale NDA accelerato se positivo.
– H1 2026: Lettura completa Part A (75-90 pazienti) e inizio trial cancro pancreatico.
– Nel 2026: Update da IIT in pancreatico e cerebrale, potenziali partnership.
– H2 2026: Possibile seconda sblocco e filing regolatori se dati supportano. Fonte:
PR Aziendali,
ClinicalTrials.gov.
Analisi del Management
Il team management di Moleculin Biotech porta esperienza estesa in startup biotech, sviluppo clinico e commercializzazione.
Walter V. Klemp – Fondatore, Presidente, CEO e Chairman
Co-fondatore con oltre 10 anni a Moleculin, Klemp ha track record comprovato in costruzione aziende biotech. Servito come CEO e Executive Chairman di Soliton, Inc., co-fondata, portata pubblica su NASDAQ 2018 e venduta a AbbVie 2020. Precedentemente, Presidente e CEO di Zeno Corporation (2004-2011), sviluppando dispositivi e farmaci dermatologia tramite approvazione FDA. Dal 1987-2000, fondato e guidato Drypers Corporation alla lista INC 500. Sua expertise in aumenti capitale e avanzamento clinico è critica per progresso fase 3 Moleculin.
Michael D. Cannon – Director
Con oltre 40 anni in farmaceutica, Cannon era Chief Science Officer e EVP a SICOR, Inc. (1997-2004), acquisita da Teva, focalizzata su generici e biopharma. Supervisato partnership internazionali e licensures facilities. Servito su multiple board, inclusa Athenex, Inc., e consiglia su investimenti healthcare.
Elizabeth Cermak – Director
Esecutivo healthcare con 35+ anni, Cermak era Chief Commercial Officer a POZEN e ruoli senior a Johnson & Johnson, gestendo portfolio $750M. Serve su board come Que Oncology e Clarus Therapeutics, portando expertise commercializzazione.
John Climaco – Director
CEO di CNS Pharmaceuticals dal 2017, Climaco ha guidato firm healthcare come Perma-Fix Medical e Axial Biotech. Serve su board inclusa Digirad, Inc., con Juris Doctorate da UC Hastings.
Robert E. George – Director
Ex partner PwC con focus healthcare, George chair Audit Committee a UT Health Science Center e insegna a UT Austin.
Joy Yan, MD, PhD – Director
Esperta oncologia con esperienza a Ambrx, Bristol Myers Squibb, Janssen e Bayer. Guidato approvazioni per nivolumab e ipilimumab. MD da China Medical University e PhD da Johns Hopkins. Fonte: Board Aziendale.
Analisti e Target Price Recenti
Consenso rating: Strong Buy da 3-4 analisti. Target prezzo medio: $24.33 (range $20-31), implicando ~430% upside da $4.59. Alcune fonti indicano medie più alte, come $61 da MarketBeat (range fino a $100) o $52 da Fintel, ma stime conservative sono usate qui basate su report consistenti. Analisti evidenziano profilo sicurezza Annamycin e potenziale trial MIRACLE. Fonte: MarketBeat, Benzinga.
Sentiment
Sentiment su MBRX è misto ma tendente bullish tra investitori retail focalizzati su catalyst. Su Reddit, discussioni evidenziano potenziale stock per run verso letture dati 2026, con alcuni che lo vedono sottovalutato a $50M market cap pre-catalyst. Viste bearish citano diluizione e lotte prezzo post-split. Su X (ex Twitter), menzioni sono sparse e spesso promozionali, con un utente che nota potenziali pattern fractal per recovery da low $3. Sentiment Stocktwits è bearish complessivo, con temi su basso volume e attesa dati trial. Nota: Queste sono opinioni da trader non professionisti e non devono essere usate per decisioni.
Rischi e Red Flags
– Alto rischio diluizione da warrant/offerte.
– Reverse split recente 1:25 (Dic 2025) segnala lotte prezzo.
– Outcomes binari trial; fallimento potrebbe affondare stock.
– Cassa bassa; potenziali ulteriori aumenti.
– Concorrenza nello spazio AML. Fonte:
PR, filing SEC.
Scenari Possibili
– Dati positivi MIRACLE: Surge stock, partnership.
– Dati negativi: Ulteriori cali, rischio delisting.
– Progresso costante: Recupero graduale a target analisti.
Sintesi Finale / Bottom Line
MBRX offre esposizione high-risk/high-reward a terapie AML con catalyst vicini. Monitora progresso trial da vicino.
Questo contenuto è per scopi educativi/informativi solo e non è consulenza finanziaria né raccomandazione di investimento. I lettori devono condurre proprie ricerche e consultare un advisor autorizzato. Conforme alle linee guida CONSOB (Italia) e SEC (USA). Per dettagli legali, vedi Merlintrader Legal.
MIRACLE Trial – Detailed Overview (Addendum)
The MIRACLE trial (Moleculin AML Registration Annamycin Combination for Leukemia Efficacy) is Moleculin Biotech’s pivotal Phase 3, multicenter, randomized, open-label study evaluating the combination of Annamycin + cytarabine (AnnAraC) versus the current standard of care venetoclax + cytarabine (VenAraC) in second-line relapsed/refractory acute myeloid leukemia (R/R AML) patients.
Key Trial Information
- NCT Number: NCT06052813
- Phase: 3 (pivotal – designed for potential NDA submission)
- Design: 1:1 randomization (AnnAraC vs VenAraC), adaptive two-part study
- Primary Endpoint: Composite complete remission rate (CR + CRi) within 6 months
- Secondary Endpoints: Overall survival (OS), event-free survival (EFS), duration of remission (DoR), MRD negativity, safety (especially cardiac toxicity)
- Enrollment Target: ~90 patients for Part A (interim), potential expansion for full pivotal
- Current Status (Jan 2026): Active recruitment, treatment completion for first 45 patients expected in Q1 2026, enrollment at ~78% for Part A (as of Dec 2025)
- Global Reach: 9 countries (USA, Italy, Poland, Spain, others), >46 active sites
- Timeline:
- Q1 2026: First unblinding / interim data (45 patients)
- H1 2026: Full Part A readout (75–90 patients)
- December 2026: Estimated primary completion
- December 2027: Study completion (follow-up)
Inclusion / Exclusion Criteria (Summary)
Inclusion: Age ≥18, confirmed R/R AML (second line), ECOG 0–2, adequate organ function, LVEF ≥50%.
Exclusion: Secondary AML (MDS or therapy-related), significant cardiac history, uncontrolled infections, pregnancy, recent BCL-2 inhibitors or experimental therapies.
Safety Profile
No cardiotoxicity observed in >90 subjects across 5 clinical trials (independent review confirmed Jan 13, 2026). Annamycin is designed to avoid typical anthracycline-induced cardiac damage.
Sources
- ClinicalTrials.gov – NCT06052813
- Moleculin Biotech Press Releases (Jan 12, 2026; Dec 2025; Nov 2025)
- SEC 10-Q (Q3 2025)
This addendum is for informational/educational purposes only. Not investment advice. Always conduct your own research and consult a licensed financial advisor.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
